Compounded Bioidentical Hormone Therapy Segmentation
The market is segmented by type into estrogen, progesterone, and testosterone, out of which, the estrogen segment is anticipated to hold the notable share in the compounded bioidentical hormone therapy market on account of growing number of women using bioidentical hormone therapy to balance their estrogen levels. The bioidentical hormone therapy helps women in reducing the adverse effects of menopause, which is the reason the global market is predicted to grow over the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Product Type |
|
|
By End-Use |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
The compounded bioidentical hormone therapy industry size is expected to register around 5.2% CAGR during the forecast period i.e., between 2025-2037.
The market growth is propelled by increasing health awareness amongst the people.
North America industry is expected to account for largest revenue share by 2037, on the back of higher healthcare expenditure, increasing thyroid prevalence amongst women, and more awareness amongst the people.
The major players in the market are Defy Medical, LLC, The biostation, Noven Pharmaceuticals, Inc., Novartis AG, and Pfizer Inc.
